Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21:309-22; PMID:22439926; http://dx.doi.org/10.1016/j.ccr.2012.02.022
   PubMed Web of Science ®Google Scholar
• Palazon A, Aragones J, Morales-Kastresana A, de Landazuri MO, Melero I. Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res 2012; 18:1207-13; PMID:22205687; http://dx.doi.org/10.1158/1078-0432.CCR-11-1591
   PubMed Web of Science ®Google Scholar
• Lardner A. The effects of extracellular pH on immune function. J Leukoc Biol 2001; 69:522-30; PMID:11310837
   PubMed Web of Science ®Google Scholar
• Singer K, Kastenberger M, Gottfried E, Hammerschmied CG, Buttner M, Aigner M, Seliger B, Walter B, Schlösser H, Hartmann A, et al. Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8(+) T-cell infiltration in the tumor. Int J Cancer 2011; 128:2085-95; PMID:20607826; http://dx.doi.org/10.1002/ijc.25543
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Karni R, Jove R, Levitzki A. Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene 1999; 18:4654-62; PMID:10467412; http://dx.doi.org/10.1038/sj.onc.1202835
   PubMed Web of Science ®Google Scholar
• Sa G, Das T, Moon C, Hilston CM, Rayman PA, Rini BI, Tannenbaum CS, Finke JH. GD3, an overexpressed tumor-derived ganglioside, mediates the apoptosis of activated but not resting T cells. Cancer Res 2009; 69:3095-104; PMID:19276353; http://dx.doi.org/10.1158/0008-5472.CAN-08-3776
   PubMed Web of Science ®Google Scholar
• Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005; 5:641-54; PMID:16056256; http://dx.doi.org/10.1038/nri1668
   PubMed Web of Science ®Google Scholar
• Igney FH, Krammer PH. Tumor counterattack: fact or fiction? Cancer Immunol Immunother 2005; 54:1127-36; PMID:15889255; http://dx.doi.org/10.1007/s00262-005-0680-7
   PubMed Web of Science ®Google Scholar
• Leone P, Shin EC, Perosa F, Vacca A, Dammacco F, Racanelli V. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst 2013; 105:1172-87; PMID:23852952; http://dx.doi.org/10.1093/jnci/djt184
   PubMed Web of Science ®Google Scholar
• Campoli M, Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 2008; 27:5869-85; PMID:18836468; http://dx.doi.org/10.1038/onc.2008.273
   PubMed Web of Science ®Google Scholar
• Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 2001; 83:117-58; PMID:11665717; http://dx.doi.org/10.1016/S0065-230X(01)83005-0
   PubMed Web of Science ®Google Scholar
• Garcia‐Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 2003; 195:346-55; PMID:12704644; http://dx.doi.org/10.1002/jcp.10290
   PubMed Web of Science ®Google Scholar
• Romero JM, Jimenez P, Cabrera T, Cozar JM, Pedrinaci S, Tallada M, Garrido F, Ruiz-Cabello F. Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. Int J Cancer 2005; 113:605-10; PMID:15455355; http://dx.doi.org/10.1002/ijc.20499
   PubMed Web of Science ®Google Scholar
• Dierssen JW, de Miranda NF, Ferrone S, van Puijenbroek M, Cornelisse CJ, Fleuren GJ, van Wezel T, Morreau H. HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression. BMC Cancer 2007; 7:33; PMID:17316446; http://dx.doi.org/10.1186/1471-2407-7-33
   PubMed Web of Science ®Google Scholar
• de Miranda NF, Nielsen M, Pereira D, van Puijenbroek M, Vasen HF, Hes FJ, van Wezel T, Morreau H. MUTYH-associated polyposis carcinomas frequently lose HLA class I expression - a common event amongst DNA-repair-deficient colorectal cancers. J Pathol 2009; 219:69-76; PMID:19462419; http://dx.doi.org/10.1002/path.2569
   PubMedGoogle Scholar
• Bicknell DC, Kaklamanis L, Hampson R, Bodmer WF, Karran P. Selection for beta 2-microglobulin mutation in mismatch repair-defective colorectal carcinomas. Curr Biol 1996; 6:1695-7; PMID:8994836; http://dx.doi.org/10.1016/S0960-9822(02)70795-1
   PubMed Web of Science ®Google Scholar
• Bennaceur K, Chapman JA, Touraine JL, Portoukalian J. Immunosuppressive networks in the tumour environment and their effect in dendritic cells. Biochim Biophys Acta 2009; 1795:16-24; PMID:18675885
   PubMed Web of Science ®Google Scholar
• Seliger B, Hohne A, Knuth A, Bernhard H, Ehring B, Tampe R, Huber C. Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. Clin Cancer Res 1996; 2:1427-33; PMID:9816317
   PubMed Web of Science ®Google Scholar
• Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today 2000; 21:455-64; PMID:10953098; http://dx.doi.org/10.1016/S0167-5699(00)01692-3
   PubMedGoogle Scholar
• Belicha-Villanueva A. Regulation of Classical and Non-classical Major Histocompatibility Complex Class I Molecules. ProQuest 2008
   Google Scholar
• Bai X-F, Liu J, Li O, Zheng P, Liu Y. Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes. J Clin Invest 2003; 111:1487-96; PMID:12750398; http://dx.doi.org/10.1172/JCI17656
   PubMed Web of Science ®Google Scholar
• Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C. Coordinate downregulation of multiple MHC class I antigen processing genes in chemical‐induced murine tumor cell lines of distinct origin. Tissue Antigens 2000; 56:327-36; PMID:11098932; http://dx.doi.org/10.1034/j.1399-0039.2000.560404.x
   PubMed Web of Science ®Google Scholar
• Ullrich E, Koch J, Cerwenka A, Steinle A. New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology 2013; 2:e26097; PMID:24353908; http://dx.doi.org/10.4161/onci.26097
   PubMed Web of Science ®Google Scholar
• Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419:734-8; PMID:12384702; http://dx.doi.org/10.1038/nature01112
   PubMed Web of Science ®Google Scholar
• Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013; 31:413-41; PMID:23298206; http://dx.doi.org/10.1146/annurev-immunol-032712-095951
   PubMed Web of Science ®Google Scholar
• Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J, Neuberg D, Anderson KC, Carrasco DR, Dranoff G. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A 2008; 105:1285-90; PMID:18202175; http://dx.doi.org/10.1073/pnas.0711293105
   PubMed Web of Science ®Google Scholar
• Marten A, von Lilienfeld-Toal M, Buchler MW, Schmidt J. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. Int J Cancer 2006; 119:2359-65; PMID:16929491; http://dx.doi.org/10.1002/ijc.22186
   PubMed Web of Science ®Google Scholar
• Salih HR, Goehlsdorf D, Steinle A. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. Hum Immunol 2006; 67:188-95; PMID:16698441; http://dx.doi.org/10.1016/j.humimm.2006.02.008
   PubMed Web of Science ®Google Scholar
• Waldhauer I, Goehlsdorf D, Gieseke F, Weinschenk T, Wittenbrink M, Ludwig A, Stevanovic S, Rammensee HG, Steinle A. Tumor-associated MICA is shed by ADAM proteases. Cancer Res 2008; 68:6368-76; PMID:18676862; http://dx.doi.org/10.1158/0008-5472.CAN-07-6768
   PubMed Web of Science ®Google Scholar
• Salih HR, Rammensee HG, Steinle A. Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding. J Immunol 2002; 169:4098-102; PMID:12370336; http://dx.doi.org/10.4049/jimmunol.169.8.4098
   PubMed Web of Science ®Google Scholar
• Clayton A, Mitchell JP, Linnane S, Mason MD, Tabi Z. Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol 2008; 180:7249-58; PMID:18490724; http://dx.doi.org/10.4049/jimmunol.180.11.7249
   PubMed Web of Science ®Google Scholar
• Fernández-Messina L, Ashiru O, Boutet P, Agüera-González S, Skepper JN, Reyburn HT, Valés-Gómez M. Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands. J Biol Chem 2010; 285:8543-51; http://dx.doi.org/10.1074/jbc.M109.045906
   PubMed Web of Science ®Google Scholar
• Waldhauer I, Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 2006; 66:2520-6; PMID:16510567; http://dx.doi.org/10.1158/0008-5472.CAN-05-2520
   PubMed Web of Science ®Google Scholar
• Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL, et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999; 285:730-2; PMID:10426994; http://dx.doi.org/10.1126/science.285.5428.730
   PubMed Web of Science ®Google Scholar
• Raffaghello L, Prigione I, Airoldi I, Camoriano M, Levreri I, Gambini C, Pende D, Steinle A, Ferrone S, Pistoia V. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 2004; 6:558-68; PMID:15548365; http://dx.doi.org/10.1593/neo.04316
   PubMed Web of Science ®Google Scholar
• Huergo-Zapico L, Acebes-Huerta A, Lopez-Soto A, Villa-Alvarez M, Gonzalez-Rodriguez AP, Gonzalez S. Molecular Bases for the Regulation of NKG2D Ligands in Cancer. Front Immunol 2014; 5:106; PMID:24711808; http://dx.doi.org/10.3389/fimmu.2014.00106
   PubMed Web of Science ®Google Scholar
• Groth A, Klöss S, Pogge von Strandmann E, Koehl U, Koch J. Mechanisms of tumor and viral immune escape from natural killer cell-mediated surveillance. J Innate Immun 2011; 3:344-54; PMID:21576922; http://dx.doi.org/10.1159/000327014
   PubMedGoogle Scholar
• Hellebrekers DM, Castermans K, Vire E, Dings RP, Hoebers NT, Mayo KH, Oude Egbrink MG, Molema G, Fuks F, van Engeland M, et al. Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res 2006; 66:10770-7; PMID:17108113; http://dx.doi.org/10.1158/0008-5472.CAN-06-1609
   PubMed Web of Science ®Google Scholar
• Piali L, Fichtel A, Terpe HJ, Imhof BA, Gisler RH. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J Exp Med 1995; 181:811-6; PMID:7530765; http://dx.doi.org/10.1084/jem.181.2.811
   PubMed Web of Science ®Google Scholar
• Wu T. The role of vascular cell adhesion molecule-1 in tumor immune evasion. Cancer Res 2007; 67:6003-6; PMID:17616653; http://dx.doi.org/10.1158/0008-5472.CAN-07-1543
   PubMed Web of Science ®Google Scholar
• Rose DM, Grabovsky V, Alon R, Ginsberg MH. The Affinity of Integrin 4 1 Governs Lymphocyte Migration. J Immunol 2001; 167:2824-30; PMID:11509628; http://dx.doi.org/10.4049/jimmunol.167.5.2824
   PubMedGoogle Scholar
• Rose DM, Han J, Ginsberg MH. α4 integrins and the immune response. Immunol Rev 2002; 186:118-24; PMID:12234367; http://dx.doi.org/10.1034/j.1600-065X.2002.18611.x
   PubMed Web of Science ®Google Scholar
• Schlesinger M, Bendas G. Vascular cell adhesion molecule‐1 (VCAM‐1)—An increasing insight into its role in tumorigenicity and metastasis. Int J Cancer 2014
   PubMed Web of Science ®Google Scholar
• Lin KY, Lu D, Hung CF, Peng S, Huang L, Jie C, Murillo F, Rowley J, Tsai YC, He L, et al. Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res 2007; 67:1832-41; PMID:17308126; http://dx.doi.org/10.1158/0008-5472.CAN-06-3014
   PubMedGoogle Scholar
• Hemmerlein B, Scherbening J, Kugler A, Radzun HJ. Expression of VCAM‐1, ICAM‐1, E‐and P‐selectin and tumour‐associated macrophages in renal cell carcinoma. Histopathology 2000; 37:78-83; PMID:10931222; http://dx.doi.org/10.1046/j.1365-2559.2000.00933.x
   PubMed Web of Science ®Google Scholar
• Vasselli JR, Shih JH, Iyengar SR, Maranchie J, Riss J, Worrell R, Torres-Cabala C, Tabios R, Mariotti A, Stearman R, et al. Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Pro Natl Acad Sci 2003; 100:6958-63; http://dx.doi.org/10.1073/pnas.1131754100
   PubMed Web of Science ®Google Scholar
• Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9:1269-74; PMID:14502282; http://dx.doi.org/10.1038/nm934
   PubMed Web of Science ®Google Scholar
• Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon K-S, Auffinger B, Tobias AL, Han Y, Lesniak MS. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res 2012; 18:6110-21; PMID:22932670; http://dx.doi.org/10.1158/1078-0432.CCR-12-2130
   PubMed Web of Science ®Google Scholar
• Astigiano S, Morandi B, Costa R, Mastracci L, D'Agostino A, Ratto GB, Melioli G, Frumento G. Eosinophil granulocytes account for indoleamine 2, 3-dioxygenase-mediated immune escape in human non small cell lung cancer. Neoplasia 2005; 7:390-6; PMID:15967116; http://dx.doi.org/10.1593/neo.04658
   PubMed Web of Science ®Google Scholar
• Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y, Ishii N, Yanaihara N, Yamada K, Takikawa O, et al. Indoleamine 2, 3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 2005; 11:6030-9; PMID:16115948; http://dx.doi.org/10.1158/1078-0432.CCR-04-2671
   PubMed Web of Science ®Google Scholar
• Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Göbel G, et al. Prognostic value of indoleamine 2, 3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 2006; 12:1144-51; PMID:16489067; http://dx.doi.org/10.1158/1078-0432.CCR-05-1966
   PubMed Web of Science ®Google Scholar
• Pan K, Wang H, Chen M-s, Zhang H-k, Weng D-s, Zhou J, Huang W, Li JJ, Song HF, Xia JC. Expression and prognosis role of indoleamine 2, 3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol 2008; 134:1247-53; PMID:18438685; http://dx.doi.org/10.1007/s00432-008-0395-1
   PubMed Web of Science ®Google Scholar
• Godin-Ethier J, Hanafi L-A, Piccirillo CA, Lapointe R. Indoleamine 2, 3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res 2011; 17:6985-91; PMID:22068654; http://dx.doi.org/10.1158/1078-0432.CCR-11-1331
   PubMed Web of Science ®Google Scholar
• Harden JL, Egilmez NK. Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity. Immunol Invest 2012; 41:738-64; PMID:23017144; http://dx.doi.org/10.3109/08820139.2012.676122
   PubMed Web of Science ®Google Scholar
• Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189:1363-72; PMID:10224276; http://dx.doi.org/10.1084/jem.189.9.1363
   PubMed Web of Science ®Google Scholar
• Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006; 176:6752-61; PMID:16709834; http://dx.doi.org/10.4049/jimmunol.176.11.6752
   PubMed Web of Science ®Google Scholar
• Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002; 196:459-68; PMID:12186838; http://dx.doi.org/10.1084/jem.20020121
   PubMed Web of Science ®Google Scholar
• Platten M, Wick W, Van den Eynde BJ. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res 2012; 72:5435-40; PMID:23090118; http://dx.doi.org/10.1158/0008-5472.CAN-12-0569
   PubMed Web of Science ®Google Scholar
• Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, Fioretti MC, Puccetti P. T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002; 9:1069-77; PMID:12232795; http://dx.doi.org/10.1038/sj.cdd.4401073
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. IDO and tolerance to tumors. Trends Mol Med 2004; 10:15-8; PMID:14720581; http://dx.doi.org/10.1016/j.molmed.2003.11.003
   PubMed Web of Science ®Google Scholar
• Terness P, Bauer TM, Röse L, Dufter C, Watzlik A, Simon H, Opelz G. Inhibition of Allogeneic T Cell Proliferation by Indoleamine 2, 3-Dioxygenase-expressing Dendritic Cells Mediation of Suppression by Tryptophan Metabolites. J Exp Med 2002; 196:447-57; PMID:12186837; http://dx.doi.org/10.1084/jem.20020052
   PubMed Web of Science ®Google Scholar
• Zoso A, Mazza EM, Bicciato S, Mandruzzato S, Bronte V, Serafini P, Inverardi L. Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion. Eur J Immunol 2014; PMID:25113564
   PubMedGoogle Scholar
• Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005; 11:312-9; PMID:15711557; http://dx.doi.org/10.1038/nm1196
   PubMed Web of Science ®Google Scholar
• Löb S, Königsrainer A, Rammensee H-G, Opelz G, Terness P. Inhibitors of indoleamine-2, 3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer 2009; 9:445-52; PMID:19461669; http://dx.doi.org/10.1038/nrc2639
   PubMed Web of Science ®Google Scholar
• Katz JB, Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 2008; 222:206-21; PMID:18364004; http://dx.doi.org/10.1111/j.1600-065X.2008.00610.x
   PubMed Web of Science ®Google Scholar
• Qian F, Villella J, Wallace PK, Mhawech-Fauceglia P, Tario JD, Andrews C, Matsuzaki J, Valmori D, Ayyoub M, Frederick PJ, et al. Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2, 3-dioxygenase-mediated arrest of T-Cell proliferation in human epithelial ovarian cancer. Cancer Res 2009; 69:5498-504; PMID:19491279; http://dx.doi.org/10.1158/0008-5472.CAN-08-2106
   PubMed Web of Science ®Google Scholar
• Suzuki S, Tone S, Takikawa O, Kubo T, Kohno I, Minatogawa Y. Expression of indoleamine 2, 3-dioxygenase and tryptophan 2, 3-dioxygenase in early concepti. Biochem J 2001; 355:425-9; PMID:11284730; http://dx.doi.org/10.1042/0264-6021:3550425
   PubMed Web of Science ®Google Scholar
• Soliman H, Mediavilla-Varela M, Antonia S. Indoleamine 2, 3-dioxygenase: is it an immune suppressor? Cancer J (Sudbury, Mass) 2010; 16; PMID:20693847
   PubMedGoogle Scholar
• Wu G, MORRIS JS. Arginine metabolism: nitric oxide and beyond. Biochem J 1998; 336:1-17; PMID:9806879
   PubMed Web of Science ®Google Scholar
• de Boniface J, Mao Y, Schmidt-Mende J, Kiessling R, Poschke I. Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients. Oncoimmunology 2012; 1:1305; PMID:23243594; http://dx.doi.org/10.4161/onci.21678
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, Ochoa AC. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009; 69:1553-60; PMID:19201693; http://dx.doi.org/10.1158/0008-5472.CAN-08-1921
   PubMed Web of Science ®Google Scholar
• Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O'Neill A, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005; 65:3044-8; PMID:15833831
   PubMed Web of Science ®Google Scholar
• Vanderstraeten A, Luyten C, Verbist G, Tuyaerts S, Amant F. Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. Cancer Immunol, Immunother 2014; 63:545-57; http://dx.doi.org/10.1007/s00262-014-1537-8
   PubMed Web of Science ®Google Scholar
• Mumenthaler SM, Yu H, Tze S, Cederbaum SD, Pegg AE, Seligson DB, Grody WW. Expression of arginase II in prostate cancer. Int J Oncol 2008; 32:357-65; PMID:18202758
   PubMed Web of Science ®Google Scholar
• Huang B, Lei Z, Zhao J, Gong W, Liu J, Chen Z, Liu Y, Li D, Yuan Y, Zhang GM, et al. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 2007; 252:86-92; PMID:17257744; http://dx.doi.org/10.1016/j.canlet.2006.12.012
   PubMed Web of Science ®Google Scholar
• Umansky V, Sevko A. Tumor microenvironment and myeloid-derived suppressor cells. Cancer Microenviron 2013; 6:169-77; PMID:23242672; http://dx.doi.org/10.1007/s12307-012-0126-7
   PubMedGoogle Scholar
• Raber P, Ochoa AC, Rodríguez PC. Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest 2012; 41:614-34; PMID:23017138; http://dx.doi.org/10.3109/08820139.2012.680634
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, Delgado A, Correa P, Brayer J, Sotomayor EM, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004; 64:5839-49; PMID:15313928; http://dx.doi.org/10.1158/0008-5472.CAN-04-0465
   PubMed Web of Science ®Google Scholar
• Munder M. Arginase: an emerging key player in the mammalian immune system. British J Pharmacol 2009; 158:638-51; PMID:19764983; http://dx.doi.org/10.1111/j.1476-5381.2009.00291.x
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 2007; 109:1568-73; PMID:17023580; http://dx.doi.org/10.1182/blood-2006-06-031856
   PubMed Web of Science ®Google Scholar
• Pervin S, Singh R, Chaudhuri G. Nitric oxide-induced cytostasis and cell cycle arrest of a human breast cancer cell line (MDA-MB-231): potential role of cyclin D1. Proc Natl Acad Sci 2001; 98:3583-8; http://dx.doi.org/10.1073/pnas.041603998
   PubMed Web of Science ®Google Scholar
• Kostourou V, Cartwright J, Johnstone A, Boult J, Cullis E, Whitley G, Robinson SP. The role of tumour-derived iNOS in tumour progression and angiogenesis. British J Cancer 2010; 104:83-90; PMID:21139581; http://dx.doi.org/10.1038/sj.bjc.6606034
   PubMedGoogle Scholar
• Mazzoni A, Bronte V, Visintin A, Spitzer JH, Apolloni E, Serafini P, Zanovello P, Segal DM. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 2002; 168:689-95; PMID:11777962; http://dx.doi.org/10.4049/jimmunol.168.2.689
   PubMed Web of Science ®Google Scholar
• Blesson S, Thiery J, Gaudin C, Stancou R, Kolb JP, Moreau JL, Theze J, Mami-Chouaib F, Chouaib S. Analysis of the mechanisms of human cytotoxic T lymphocyte response inhibition by NO. Int Immunol 2002; 14:1169-78; PMID:12356682; http://dx.doi.org/10.1093/intimm/dxf081
   PubMed Web of Science ®Google Scholar
• Munder M, Schneider H, Luckner C, Giese T, Langhans C-D, Fuentes JM, Kropf P, Mueller I, Kolb A, Modolell M, et al. Suppression of T-cell functions by human granulocyte arginase. Blood 2006; 108:1627-34
   PubMed Web of Science ®Google Scholar
• Tenu J-P, Lepoivre M, Moali C, Brollo M, Mansuy D, Boucher J-L. Effects of the New Arginase Inhibitor N ω-Hydroxy-nor-l-Arginine on NO Synthase Activity in Murine Macrophages. Nitric Oxide 1999; 3:427-38; PMID:10637120; http://dx.doi.org/10.1006/niox.1999.0255
   PubMed Web of Science ®Google Scholar
• Kitayama J, Emoto S, Yamaguchi H, Ishigami H, Yamashita H, Seto Y, Matsuzaki K, Watanabe T. CD90 (+) CD45 (−) intraperitoneal mesothelial-like cells inhibit T cell activation by production of arginase I. Cell Immunol 2014; 288:8-14; PMID:24556645; http://dx.doi.org/10.1016/j.cellimm.2014.01.008
   PubMedGoogle Scholar
• Wang R. Innate immune regulation and cancer immunotherapy. Springer, 2012.
   Google Scholar
• Zhu X, Pribis JP, Rodriguez PC, Morris Jr SM, Vodovotz Y, Billiar TR, Ochoa JB. The central role of arginine catabolism in T-cell dysfunction and increased susceptibility to infection after physical injury. Ann Surg 2014; 259:171-8; PMID:23470573; http://dx.doi.org/10.1097/SLA.0b013e31828611f8
   PubMed Web of Science ®Google Scholar
• Kusmartsev SA, Li Y, Chen S-H. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol 2000; 165:779-85; PMID:10878351; http://dx.doi.org/10.4049/jimmunol.165.2.779
   PubMed Web of Science ®Google Scholar
• Zhou R, He PL, Ren YX, Wang WH, Zhou RY, Wan H, Ono S, Fujiwara H, Zuo JP. Myeloid suppressor cell‐associated immune dysfunction in CSA1M fibrosarcoma tumor‐bearing mice. Cancer Sci 2007; 98:882-9; PMID:17433038; http://dx.doi.org/10.1111/j.1349-7006.2007.00465.x
   PubMed Web of Science ®Google Scholar
• Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, Dolcetti L, Bronte V, Borrello I. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006; 203:2691-702; PMID:17101732; http://dx.doi.org/10.1084/jem.20061104
   PubMed Web of Science ®Google Scholar
• Ibiza S, Serrador J. The role of nitric oxide in the regulation of adaptive immune responses. Inmunología 2008; 27:103-17
   Google Scholar
• Sosroseno W, Herminajeng E, Bird P, Seymour G. l‐arginine‐dependent nitric oxide production of a murine macrophage‐like RAW 264.7 cell line stimulated with Porphyromonas gingivalis lipopolysaccharide. Oral Microbiol Immunol 2004; 19:65-70; PMID:14871343; http://dx.doi.org/10.1046/j.0902-0055.2003.00108.x
   PubMedGoogle Scholar
• Spiegel S, Merrill AH, Jr. Sphingolipid metabolism and cell growth regulation. Faseb J 1996; 10:1388-97; PMID:8903509
   PubMed Web of Science ®Google Scholar
• Krengel U, Bousquet PA. Molecular recognition of gangliosides and their potential for cancer immunotherapies. Front Immunol 2014; 5:325; PMID:25101077; http://dx.doi.org/10.3389/fimmu.2014.00325
   PubMed Web of Science ®Google Scholar
• McKallip R, Li R, Ladisch S. Tumor gangliosides inhibit the tumor-specific immune response. J Immunol 1999; 163:3718-26; PMID:10490967
   PubMed Web of Science ®Google Scholar
• Li R, Villacreses N, Ladisch S. Human tumor gangliosides inhibit murine immune responses in vivo. Cancer Res 1995; 55:211-4; PMID:7812945
   PubMedGoogle Scholar
• Biswas S, Biswas K, Richmond A, Ko J, Ghosh S, Simmons M, Rayman P, Rini B, Gill I, Tannenbaum CS, et al. Elevated levels of select gangliosides in T cells from renal cell carcinoma patients is associated with T cell dysfunction. J Immunol 2009; 183:5050-8; PMID:19801523; http://dx.doi.org/10.4049/jimmunol.0900259
   PubMed Web of Science ®Google Scholar
• Das T, Sa G, Paszkiewicz-Kozik E, Hilston C, Molto L, Rayman P, Kudo D, Biswas K, Bukowski RM, Finke JH, et al. Renal cell carcinoma tumors induce T cell apoptosis through receptor-dependent and receptor-independent pathways. J Immunol 2008; 180:4687-96; PMID:18354192; http://dx.doi.org/10.4049/jimmunol.180.7.4687
   PubMed Web of Science ®Google Scholar
• Raval G, Biswas S, Rayman P, Biswas K, Sa G, Ghosh S, Thornton M, Hilston C, Das T, Bukowski R, et al. TNF-alpha induction of GM2 expression on renal cell carcinomas promotes T cell dysfunction. J Immunol 2007; 178:6642-52; PMID:17475896; http://dx.doi.org/10.4049/jimmunol.178.10.6642
   PubMedGoogle Scholar
• Uzzo RG, Rayman P, Kolenko V, Clark PE, Cathcart MK, Bloom T, Novick AC, Bukowski RM, Hamilton T, Finke JH. Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. J Clin Invest 1999; 104:769-76; PMID:10491412; http://dx.doi.org/10.1172/JCI6775
   PubMed Web of Science ®Google Scholar
• Rayman P, Wesa AK, Richmond AL, Das T, Biswas K, Raval G, Storkus WJ, Tannenbaum C, Novick A, Bukowski R, et al. Effect of renal cell carcinomas on the development of type 1 T-cell responses. Clin Cancer Res 2004; 10:6360S-6S; PMID:15448031; http://dx.doi.org/10.1158/1078-0432.CCR-050011
   PubMed Web of Science ®Google Scholar
• Biswas K, Richmond A, Rayman P, Biswas S, Thornton M, Sa G, Das T, Zhang R, Chahlavi A, Tannenbaum CS, et al. GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction. Cancer Res 2006; 66:6816-25; PMID:16818659; http://dx.doi.org/10.1158/0008-5472.CAN-06-0250
   PubMed Web of Science ®Google Scholar
• Crespo FA, Sun X, Cripps JG, Fernandez-Botran R. The immunoregulatory effects of gangliosides involve immune deviation favoring type-2 T cell responses. J Leukoc Biol 2006; 79:586-95; PMID:16415169; http://dx.doi.org/10.1189/jlb.0705395
   PubMedGoogle Scholar
• Caldwell S, Heitger A, Shen W, Liu Y, Taylor B, Ladisch S. Mechanisms of ganglioside inhibition of APC function. J Immunol 2003; 171:1676-83; PMID:12902465; http://dx.doi.org/10.4049/jimmunol.171.4.1676
   PubMed Web of Science ®Google Scholar
• Thornton MV, Kudo D, Rayman P, Horton C, Molto L, Cathcart MK, Ng C, Paszkiewicz-Kozik E, Bukowski R, Derweesh I, et al. Degradation of NF-kappa B in T cells by gangliosides expressed on renal cell carcinomas. J Immunol 2004; 172:3480-90; PMID:15004148; http://dx.doi.org/10.4049/jimmunol.172.6.3480
   PubMedGoogle Scholar
• Lee HC, Wondimu A, Liu Y, Ma JS, Radoja S, Ladisch S. Ganglioside inhibition of CD8+ T cell cytotoxicity: interference with lytic granule trafficking and exocytosis. J Immunol 2012; 189:3521-7; PMID:22956583; http://dx.doi.org/10.4049/jimmunol.1201256
   PubMed Web of Science ®Google Scholar
• Retter MW, Johnson JC, Peckham DW, Bannink JE, Bangur CS, Dresser K, Cai F, Foy TM, Fanger NA, Fanger GR, et al. Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts. Cancer Res 2005; 65:6425-34; PMID:16024647; http://dx.doi.org/10.1158/0008-5472.CAN-05-0300
   PubMedGoogle Scholar
• Lloyd KO, Gordon CM, Thampoe IJ, DiBenedetto C. Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition of the cells. Cancer Res 1992; 52:4948-53; PMID:1516051
   PubMed Web of Science ®Google Scholar
• Mazorra Z, Mesa C, Fernández LE. GM3 ganglioside: a novel target for the therapy against melanoma. Biotecnología Aplicada 2009; 26:256-9
   Google Scholar
• Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, Old LJ. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A 1985; 82:1242-6; PMID:3883355; http://dx.doi.org/10.1073/pnas.82.4.1242
   PubMed Web of Science ®Google Scholar
• Cheung NK, Neely JE, Landmeier B, Nelson D, Miraldi F. Targeting of ganglioside GD2 monoclonal antibody to neuroblastoma. J Nucl Med 1987; 28:1577-83; PMID:3655911
   PubMed Web of Science ®Google Scholar
• Ahmed M, Cheung N-KV. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett 588:288-97; PMID:24295643
   PubMedGoogle Scholar
• Fernandez LE, Gabri MR, Guthmann MD, Gomez RE, Gold S, Fainboim L, Gomez DE, Alonso DF. NGcGM3 ganglioside: a privileged target for cancer vaccines. J Immunol Res 2010; 2010:814397
   Google Scholar
• Groux H, Bigler M, de Vries JE, Roncarolo M-G. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol 1998; 160:3188-93; PMID:9531274
   PubMed Web of Science ®Google Scholar
• Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukocyte Biol 2005; 78:1043-51; PMID:16204623; http://dx.doi.org/10.1189/jlb.0705358
   PubMed Web of Science ®Google Scholar
• Kim J, Modlin RL, Moy RL, Dubinett SM, McHugh T, Nickoloff BJ, Uyemura K. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol 1995; 155:2240-7; PMID:7636270
   PubMed Web of Science ®Google Scholar
• Huang M, Wang J, Lee P, Sharma S, Mao JT, Meissner H, Uyemura K, Modlin R, Wollman J, Dubinett SM. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res 1995; 55:3847-53; PMID:7641203
   PubMed Web of Science ®Google Scholar
• Knoefel B, Nuske K, Steiner T, Junker K, Kosmehl H, Rebstock K, Reinhold D, Junker U. Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-beta 1 in primary cultures and modulate T lymphocyte blast transformation. J Interferon Cytokine Res 1997; 17:95-102; PMID:9058315; http://dx.doi.org/10.1089/jir.1997.17.95
   PubMed Web of Science ®Google Scholar
• Venetsanakos E, Beckman I, Bradley J, Skinner JM. High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours. Br J Cancer 1997; 75:1826-30; PMID:9192989; http://dx.doi.org/10.1038/bjc.1997.311
   PubMed Web of Science ®Google Scholar
• Pisa P, Halapi E, Pisa EK, Gerdin E, Hising C, Bucht A, Gerdin B, Kiessling R. Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. Proc Natl Acad Sci U S A 1992; 89:7708-12; PMID:1502188; http://dx.doi.org/10.1073/pnas.89.16.7708
   PubMed Web of Science ®Google Scholar
• Bolpetti A, Silva JS, Villa LL, Lepique AP. Interleukin-10 production by tumor infiltrating macrophages plays a role in Human Papillomavirus 16 tumor growth. BMC Immunol 2010; 11:27; PMID:20525400; http://dx.doi.org/10.1186/1471-2172-11-27
   PubMed Web of Science ®Google Scholar
• Yue FY, Dummer R, Geertsen R, Hofbauer G, Laine E, Manolio S, Burg G. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 1997; 71:630-7; PMID:9178819; http://dx.doi.org/10.1002/(SICI)1097-0215(19970516)71:4%3c630::AID-IJC20%3e3.0.CO;2-E
   PubMed Web of Science ®Google Scholar
• Fujieda S, Sunaga H, Tsuzuki H, Fan GK, Saito H. IL-10 expression is associated with the expression of platelet-derived endothelial cell growth factor and prognosis in oral and oropharyngeal carcinoma. Cancer Lett 1999; 136:1-9; PMID:10211932; http://dx.doi.org/10.1016/S0304-3835(98)00281-X
   PubMed Web of Science ®Google Scholar
• Sher A, Fiorentino D, Caspar P, Pearce E, Mosmann T. Production of IL-10 by CD4+ T lymphocytes correlates with down-regulation of Th1 cytokine synthesis in helminth infection. J Immunol 1991; 147:2713-6; PMID:1680917
   PubMed Web of Science ®Google Scholar
• de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174:1209-20; PMID:1940799; http://dx.doi.org/10.1084/jem.174.5.1209
   PubMed Web of Science ®Google Scholar
• Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA. Mechanisms of immune suppression by interleukin‐10 and transforming growth factor‐β: the role of T regulatory cells. Immunology 2006; 117:433-42; PMID:16556256; http://dx.doi.org/10.1111/j.1365-2567.2006.02321.x
   PubMed Web of Science ®Google Scholar
• Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21:685-711; PMID:12615891; http://dx.doi.org/10.1146/annurev.immunol.21.120601.141040
   PubMed Web of Science ®Google Scholar
• Nabarro S, Himoudi N, Papanastasiou A, Gilmour K, Gibson S, Sebire N, Thrasher A, Blundell MP, Hubank M, Canderan G, et al. Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein. J Exp Med 2005; 202:1399-410; PMID:16287709; http://dx.doi.org/10.1084/jem.20050730
   PubMed Web of Science ®Google Scholar
• Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004; 10:48-54; PMID:14702634; http://dx.doi.org/10.1038/nm976
   PubMed Web of Science ®Google Scholar
• Sevko A, Umansky V. Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. J Cancer 2013; 4:3-11; PMID:23386900; http://dx.doi.org/10.7150/jca.5047
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506
   PubMed Web of Science ®Google Scholar
• Baj-Krzyworzeka M, Baran J, Szatanek R, Stankiewicz D, Siedlar M, Zembala M. Prevention and reversal of tumor cell-induced monocyte deactivation by cytokines, purified protein derivative (PPD), and anti-IL-10 antibody. Cancer immun 2004; 4:8; PMID:15327279
   PubMedGoogle Scholar
• Nishijima K-i, Hisatsune T, Minai Y, Kohyama M, Kaminogawa S. Anti-IL-10 Antibody Enhances the Proliferation of CD8+ T Cell Clones: Autoregulatory Role of Murine IL-10 in CD8+ T Cells. Cell Immunol 1994; 154:193-201; PMID:8118887; http://dx.doi.org/10.1006/cimm.1994.1068
   PubMedGoogle Scholar
• Avradopoulos K, Mehta S, Blackinton D, Wanebo HJ. Interleukin-10 as a possible mediator of immunosuppressive effect in patients with squamous cell carcinoma of the head and neck. Ann Surg Oncol 1997; 4:184-90; PMID:9084857; http://dx.doi.org/10.1007/BF02303803
   PubMed Web of Science ®Google Scholar
• Sato T, Terai M, Tamura Y, Alexeev V, Mastrangelo MJ, Selvan SR. Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res 2011; 51:170-82; PMID:22139852; http://dx.doi.org/10.1007/s12026-011-8262-6
   PubMed Web of Science ®Google Scholar
• Lee TL, Yeh J, Van Waes C, Chen Z. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Mol Cancer Ther 2006; 5:8-19; PMID:16432158; http://dx.doi.org/10.1158/1535-7163.MCT-05-0069
   PubMed Web of Science ®Google Scholar
• Alexander WS. Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2002; 2:410-6; PMID:12093007
   PubMed Web of Science ®Google Scholar
• Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we? 2009.
   Google Scholar
• Wang S, Yang D, Lippman ME. Targeting Bcl-2 and Bcl-X L with nonpeptidic small-molecule antagonists. Semin Oncol, 2003; 30: 133-42; http://dx.doi.org/10.1053/j.seminoncol.2003.08.015
   PubMed Web of Science ®Google Scholar
• Mohammad RM, Wang S, Aboukameel A, Chen B, Wu X, Chen J, Al-Katib A. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL ; (−)-gossypol against diffuse large cell lymphoma. Mol Cancer Ther 2005; 4:13-21; PMID:15657349; http://dx.doi.org/10.1186/1476-4598-4-13
   PubMedGoogle Scholar
• Mohammad RM, Goustin AS, Aboukameel A, Chen B, Banerjee S, Wang G, Nikolovska-Coleska Z, Wang S, Al-Katib A. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res 2007; 13:2226-35; PMID:17404107; http://dx.doi.org/10.1158/1078-0432.CCR-06-1574
   PubMed Web of Science ®Google Scholar
• Oh SA, Li MO. TGF-beta: guardian of T cell function. J Immunol 2013; 191:3973-9; PMID:24098055; http://dx.doi.org/10.4049/jimmunol.1301843
   PubMed Web of Science ®Google Scholar
• Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat Med 2001; 7:1118-22; PMID:11590434; http://dx.doi.org/10.1038/nm1001-1118
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Strobl S, Young H, Ortaldo J, Ochoa A. Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta. J Immunol 1991; 146:3289-97; PMID:1827481
   PubMed Web of Science ®Google Scholar
• Cheng M-L, Chen H-W, Tsai J-P, Lee Y-P, Shih Y-C, Chang C-M, Ting CC. Clonal restriction of the expansion of antigen-specific CD8+ memory T cells by transforming growth factor-β. J leukocyte Biol 2006; 79:1033-42; PMID:16478921; http://dx.doi.org/10.1189/jlb.0805474
   PubMedGoogle Scholar
• Letterio JJ, Roberts AB. Regulation of immune responses by TGF-β*. Ann Rev Immunol 1998; 16:137-61; PMID:9597127; http://dx.doi.org/10.1146/annurev.immunol.16.1.137
   PubMed Web of Science ®Google Scholar
• Bright JJ, Sriram S. TGF-β inhibits IL-12-induced activation of Jak-STAT pathway in T lymphocytes. J Immunol 1998; 161:1772-7; PMID:9712043
   PubMed Web of Science ®Google Scholar
• Holter W, Kalthoff F, Pickl W, Ebner C, Majdic O, Kraft D, Knapp W. Transforming growth factor-beta inhibits IL-4 and IFN-gamma production by stimulated human T cells. Int Immunol 1994; 6:469; PMID:8186198; http://dx.doi.org/10.1093/intimm/6.3.469
   PubMed Web of Science ®Google Scholar
• Peng Y, Laouar Y, Li MO, Green EA, Flavell RA. TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci U S A 2004; 101:4572-7; PMID:15070759; http://dx.doi.org/10.1073/pnas.0400810101
   PubMed Web of Science ®Google Scholar
• Chen W, Jin W, Hardegen N, Lei K-j, Li L, Marinos N, McGrady G, Wahl SM. Conversion of peripheral CD4+ CD25− naive T cells to CD4+ CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 2003; 198:1875-86; PMID:14676299; http://dx.doi.org/10.1084/jem.20030152
   PubMed Web of Science ®Google Scholar
• Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. Cutting edge: TGF-β induces a regulatory phenotype in CD4+ CD25− T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 2004; 172:5149-53; PMID:15100250; http://dx.doi.org/10.4049/jimmunol.172.9.5149
   PubMed Web of Science ®Google Scholar
• Chalmin F, Mignot G, Bruchard M, Chevriaux A, Vegran F, Hichami A, Ladoire S, Derangère V, Vincent J, Masson D, et al. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity 2012; 36:362-73; PMID:22406269; http://dx.doi.org/10.1016/j.immuni.2011.12.019
   PubMed Web of Science ®Google Scholar
• Kryczek I, Zhao E, Liu Y, Wang Y, Vatan L, Szeliga W, Moyer J, Klimczak A, Lange A, Zou W. Human TH17 cells are long-lived effector memory cells. Sci Trans Med 2011; 3:104ra0; http://dx.doi.org/10.1126/scitranslmed.3002949
   Web of Science ®Google Scholar
• Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009; 114:1141-9; PMID:19470694; http://dx.doi.org/10.1182/blood-2009-03-208249
   PubMed Web of Science ®Google Scholar
• Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, Sanchez-Perez L, Sukumar M, Reger RN, Yu Z, Kern SJ, et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 2011; 35:972-85; PMID:22177921; http://dx.doi.org/10.1016/j.immuni.2011.09.019
   PubMed Web of Science ®Google Scholar
• Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW, Dong C. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009; 31:787-98; PMID:19879162; http://dx.doi.org/10.1016/j.immuni.2009.09.014
   PubMed Web of Science ®Google Scholar
• Viaud S, Flament C, Zoubir M, Pautier P, LeCesne A, Ribrag V, Soria JC, Marty V, Vielh P, Robert C, et al. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res 2011; 71:661-5; PMID:21148486; http://dx.doi.org/10.1158/0008-5472.CAN-10-1259
   PubMed Web of Science ®Google Scholar
• Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T, Steinbrecher A, Brawanski A, Proescholdt M, Schlaier J, Buchroithner J, et al. Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 2007; 17:201-12; PMID:17638524; http://dx.doi.org/10.1089/oli.2006.0053
   PubMed Web of Science ®Google Scholar
• Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression by TGF-beta inhibitors. Invest New Drugs 2003; 21:21-32; PMID:12795527; http://dx.doi.org/10.1023/A:1022951824806
   PubMed Web of Science ®Google Scholar
• Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-β targeted cancer therapy. Int J Biol Sci 2012; 8:964; PMID:22811618; http://dx.doi.org/10.7150/ijbs.4564
   PubMed Web of Science ®Google Scholar
• Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007; 67:4507-13; PMID:17483367; http://dx.doi.org/10.1158/0008-5472.CAN-06-4174
   PubMed Web of Science ®Google Scholar
• Wang M-T, Honn KV, Nie D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Meta Rev 2007; 26:525-34; PMID:17763971; http://dx.doi.org/10.1007/s10555-007-9096-5
   PubMed Web of Science ®Google Scholar
• Sreeramkumar V, Fresno M, Cuesta N. Prostaglandin E2 and T cells: friends or foes&quest. Immunol Cell Biol 2011; 90:579-86; PMID:21946663; http://dx.doi.org/10.1038/icb.2011.75
   PubMedGoogle Scholar
• Betz M, Fox BS. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol 1991; 146:108-13; PMID:1845802
   PubMed Web of Science ®Google Scholar
• Snijdewint F, Kaliński P, Wierenga E, Bos J, Kapsenberg M. Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J Immunol 1993; 150:5321-9; PMID:8390534
   PubMed Web of Science ®Google Scholar
• Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, Wollman J, Herschman H, Dubinett SM. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998; 58:1208-16; PMID:9515807
   PubMed Web of Science ®Google Scholar
• Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, Zhu L, Kronenberg M, Miller PW, Portanova J, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000; 164:361-70; PMID:10605031; http://dx.doi.org/10.4049/jimmunol.164.1.361
   PubMed Web of Science ®Google Scholar
• Luo JS, Kammerer R, von Kleist S. Comparison of the effects of immunosuppressive factors from newly established colon carcinoma cell cultures on human lymphocyte proliferation and cytokine secretion. Tumour Biol 2000; 21:11-20; PMID:10601837; http://dx.doi.org/10.1159/000030106
   PubMedGoogle Scholar
• Khan I, Al-Awadi F, Thomas N, Haridas S, Anim J. Cyclooxygenase-2 inhibition and experimental colitis: beneficial effects of phosphorothioated antisense oligonucleotide and meloxicam. Scand J Gastroenterol 2002; 37:1428-36; PMID:12523593; http://dx.doi.org/10.1080/003655202762671314
   PubMed Web of Science ®Google Scholar
• Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM, Karin M. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011; 470:548-53; PMID:21326202; http://dx.doi.org/10.1038/nature09707
   PubMed Web of Science ®Google Scholar
• Zhao E, Wang L, Dai J, Kryczek I, Wei S, Vatan L, Altuwaijri S, Sparwasser T, Wang G, Keller ET, et al. Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. Oncoimmunology 2012; 1:152-61; PMID:22720236; http://dx.doi.org/10.4161/onci.1.2.18480
   PubMed Web of Science ®Google Scholar
• Watanabe J, Kushihata F, Honda K, Sugita A, Tateishi N, Mominoki K, Matsuda S, Kobayashi N. Prognostic significance of Bcl-xL in human hepatocellular carcinoma. Surgery 2004; 135:604-12; PMID:15179366; http://dx.doi.org/10.1016/j.surg.2003.11.015
   PubMed Web of Science ®Google Scholar
• Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22:8581-9; PMID:14634620; http://dx.doi.org/10.1038/sj.onc.1207113
   PubMed Web of Science ®Google Scholar
• Kleinberg L, Lie AK, Florenes VA, Nesland JM, Davidson B. Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma. Hum Pathol 2007; 38:986-94; PMID:17350081; http://dx.doi.org/10.1016/j.humpath.2006.12.013
   PubMed Web of Science ®Google Scholar
• Mizutani Y, Nakanishi H, Li YN, Matsubara H, Yamamoto K, Sato N, Shiraishi T, Nakamura T, Mikami K, Okihara K, et al. Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int J Oncol 2007; 30:919-25; PMID:17332931
   PubMed Web of Science ®Google Scholar
• Guan J, Chen J. Survivin-a new tumor-specific anti-apoptosis factor. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2001; 23:532-4; PMID:12905879
   PubMedGoogle Scholar
• Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 2007; 28:1133-9; PMID:17341657; http://dx.doi.org/10.1093/carcin/bgm047
   PubMed Web of Science ®Google Scholar
• Noh KH, Kang TH, Kim JH, Pai SI, Lin KY, Hung C-F, Wu TC, Kim TW. Activation of Akt as a mechanism for tumor immune evasion. Mol Ther 2008; 17:439-47; PMID:19107122; http://dx.doi.org/10.1038/mt.2008.255
   PubMedGoogle Scholar
• Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7:41-51; PMID:17186030; http://dx.doi.org/10.1038/nri1995
   PubMed Web of Science ®Google Scholar
• Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Trans Med 2012; 4:127ra37; PMID:22461641; http://dx.doi.org/10.1126/scitranslmed.3003689
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24:207-12; PMID:22236695; http://dx.doi.org/10.1016/j.coi.2011.12.009
   PubMed Web of Science ®Google Scholar
• Cao Y, Zhang L, Ritprajak P, Tsushima F, Youngnak-Piboonratanakit P, Kamimura Y, Hashiguchi M, Azuma M. Immunoregulatory molecule B7-H1 (CD274) contributes to skin carcinogenesis. Cancer Res 2011; 71:4737-41; PMID:21730022; http://dx.doi.org/10.1158/0008-5472.CAN-11-0527
   PubMedGoogle Scholar
• Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26:677-704; PMID:18173375; http://dx.doi.org/10.1146/annurev.immunol.26.021607.090331
   PubMed Web of Science ®Google Scholar
• Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010; 236:219-42; PMID:20636820; http://dx.doi.org/10.1111/j.1600-065X.2010.00923.x
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8:793-800; PMID:12091876; http://dx.doi.org/10.1038/nm0902-1039c
   PubMed Web of Science ®Google Scholar
• Sugasawa H, Ichikura T, Tsujimoto H, Kinoshita M, Morita D, Ono S, Chochi K, Tsuda H, Seki S, Mochizuki H. Prognostic significance of expression of CCL5/RANTES receptors in patients with gastric cancer. J Surg Oncol 2008; 97:445-50; PMID:18297689; http://dx.doi.org/10.1002/jso.20984
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003; 9:562-7; PMID:12704383; http://dx.doi.org/10.1038/nm863
   PubMed Web of Science ®Google Scholar
• Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006; 203:871-81; PMID:16606666; http://dx.doi.org/10.1084/jem.20050930
   PubMed Web of Science ®Google Scholar
• Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, Salomao D, Cheville J, Hirano F, Lin W, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003; 63:6501-5; PMID:14559843
   PubMed Web of Science ®Google Scholar
• Li N, Qin H, Li X, Zhou C, Wang D, Ma W, Lin C, Zhang Y, Wang S, Zhang S. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1. J Clin Immunol 2007; 27:117-30; PMID:17180470; http://dx.doi.org/10.1007/s10875-006-9053-z
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44; PMID:23724846; http://dx.doi.org/10.1056/NEJMoa1305133
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167-75; PMID:20516446; http://dx.doi.org/10.1200/JCO.2009.26.7609
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
   PubMed Web of Science ®Google Scholar
• Flies DB, Sandler BJ, Sznol M, Chen L. Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. The Yale J Biol Med 2011; 84:409; PMID:22180678
   PubMedGoogle Scholar
• Ascierto PA, Simeone E, Sznol M, Fu Y-X, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010; 37:508-16; http://dx.doi.org/10.1053/j.seminoncol.2010.09.008
   PubMed Web of Science ®Google Scholar
• Ichikawa M, Chen L. Role of B7-H1 and B7-H4 molecules in down-regulating effector phase of T-cell immunity: novel cancer escaping mechanisms. Front Biosci 2005; 10:2856-60; PMID:15970540; http://dx.doi.org/10.2741/1742
   PubMed Web of Science ®Google Scholar
• Geng H, Zhang GM, Xiao H, Yuan Y, Li D, Zhang H, Qiu H, He YF, Feng ZH. HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma. Int J Cancer 2006; 118:2657-64; PMID:16425224; http://dx.doi.org/10.1002/ijc.21795
   PubMed Web of Science ®Google Scholar
• Soares KC, Zheng L, Edil B, Jaffee EM. Vaccines for pancreatic cancer. Cancer J (Sudbury, Mass) 2012; 18:642; PMID:23187853; http://dx.doi.org/10.1097/PPO.0b013e3182756903
   PubMed Web of Science ®Google Scholar
• Smith JB, Stashwick C, Powell DJ, Jr. B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look. Gynecol Oncol 2014; 134:181-9; PMID:24657487; http://dx.doi.org/10.1016/j.ygyno.2014.03.553
   PubMedGoogle Scholar
• Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, Chapoval AI, Flies DB, Bajorath J, Chen L. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 2003; 18:849-61; PMID:12818165; http://dx.doi.org/10.1016/S1074-7613(03)00152-3
   PubMed Web of Science ®Google Scholar
• Murooka TT, Wong MM, Rahbar R, Majchrzak-Kita B, Proudfoot AE, Fish EN. CCL5-CCR5-mediated Apoptosis in T cells requirement for glycosaminoglycan binding and CCL5 aggregation. J Biol Chem 2006; 281:25184-94; PMID:16807236; http://dx.doi.org/10.1074/jbc.M603912200
   PubMed Web of Science ®Google Scholar
• Roth W, Reed JC. FLIP protein and TRAIL-induced apoptosis. Vitamins & Hormones 2004; 67:189-206; PMID:15110178; http://dx.doi.org/10.1016/S0083-6729(04)67011-7
   PubMed Web of Science ®Google Scholar
• French LE, Tschopp J. The TRAIL to selective tumor death. Nat Med 1999; 5:146-7; PMID:9930856; http://dx.doi.org/10.1038/5505
   PubMed Web of Science ®Google Scholar
• Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003; 22:8628-33; PMID:14634624; http://dx.doi.org/10.1038/sj.onc.1207232
   PubMed Web of Science ®Google Scholar
• Marsters SA, Pitti RM, Donahue CJ, Ruppert S, Bauer KD, Ashkenazi A. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr Biol 1996; 6:750-2; PMID:8793301; http://dx.doi.org/10.1016/S0960-9822(09)00456-4
   PubMed Web of Science ®Google Scholar
• Jeremias I, Herr I, Boehler T, Debatin KM. TRAIL/Apo‐2‐ligand‐induced apoptosis in human T cells. Euro J Immunol 1998; 28:143-52; PMID:9485194; http://dx.doi.org/10.1002/(SICI)1521-4141(199801)28:01%3c143::AID-IMMU143%3e3.0.CO;2-3
   PubMedGoogle Scholar
• Hallermalm K, De Geer A, Kiessling R, Levitsky V, Levitskaya J. Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes. Cancer Res 2004; 64:6775-82; PMID:15374996; http://dx.doi.org/10.1158/0008-5472.CAN-04-0508
   PubMed Web of Science ®Google Scholar
• Schall TJ, Bacon KB. Chemokines, leukocyte trafficking, and inflammation. Curr Opin Immunol 1994; 6:865-73; PMID:7710711; http://dx.doi.org/10.1016/0952-7915(94)90006-X
   PubMed Web of Science ®Google Scholar
• Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies-integrating mammalian biology. Cell 2001; 104:487-501; PMID:11239407; http://dx.doi.org/10.1016/S0092-8674(01)00237-9
   PubMed Web of Science ®Google Scholar
• Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, Mordoh J, Fainboim L, Podhajcer OL, Rabinovich GA. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 2004; 5:241-51; PMID:15050916; http://dx.doi.org/10.1016/S1535-6108(04)00024-8
   PubMed Web of Science ®Google Scholar
• Giovarelli M, Musiani P, Garotta G, Ebner R, Di Carlo E, Kim Y, Cappello P, Rigamonti L, Bernabei P, Novelli F, et al. A “stealth effect”: adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions. J Immunol 1999; 163:4886-93; PMID:10528190
   PubMed Web of Science ®Google Scholar
• Nakashima M, Sonoda K, Watanabe T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med 1999; 5:938-42; PMID:10426319; http://dx.doi.org/10.1038/11383
   PubMed Web of Science ®Google Scholar
• Umata T, Hirata M, Takahashi T, Ryu F, Shida S, Takahashi Y, Tsuneoka M, Miura Y, Masuda M, Horiguchi Y, et al. A dual signaling cascade that regulates the ectodomain shedding of heparin-binding epidermal growth factor-like growth factor. J Biol Chem 2001; 276:30475-82; PMID:11402047; http://dx.doi.org/10.1074/jbc.M103673200
   PubMedGoogle Scholar
• Igney FH, Behrens CK, Krammer PH. CD95L mediates tumor counterattack in vitro but induces neutrophil-independent tumor rejection in vivo. Int J Cancer 2005; 113:78-87; PMID:15386427; http://dx.doi.org/10.1002/ijc.20538
   PubMed Web of Science ®Google Scholar
• Ryan AE, Shanahan F, O'Connell J, Houston AM. Addressing the “Fas counterattack” controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res 2005; 65:9817-23; PMID:16267003; http://dx.doi.org/10.1158/0008-5472.CAN-05-1462
   PubMed Web of Science ®Google Scholar
• Aubrey M. Glycans in cell interaction and recognition. CRC Press, 2003.
   Google Scholar
• Elola M, Wolfenstein-Todel C, Troncoso M, Vasta G, Rabinovich G. Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci 2007; 64:1679-700; PMID:17497244; http://dx.doi.org/10.1007/s00018-007-7044-8
   PubMed Web of Science ®Google Scholar
• Moiseeva EP, Spring EL, Baron JH, de Bono D. Galectin 1 modulates attachment, spreading and migration of cultured vascular smooth muscle cells via interactions with cellular receptors and components ofextracellu lar matrix. J Vasc Res 1999; 36:47-58; PMID:10050073; http://dx.doi.org/10.1159/000025625
   PubMedGoogle Scholar
• Liu F-T. Galectins: a new family of regulators of inflammation. Clin Immunol 2000; 97:79-88; PMID:11027447; http://dx.doi.org/10.1006/clim.2000.4912
   PubMed Web of Science ®Google Scholar
• Liu F-T. Regulatory roles of galectins in the immune response. Int Arch Allergy Immunol 2005; 136:385-400; PMID:15775687; http://dx.doi.org/10.1159/000084545
   PubMed Web of Science ®Google Scholar
• Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S, Verhofstad N, Nakabeppu Y, Baum LG, Bakkers J, et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci 2006; 103:15975-80; http://dx.doi.org/10.1073/pnas.0603883103
   PubMed Web of Science ®Google Scholar
• Thijssen VL, Barkan B, Shoji H, Aries IM, Mathieu V, Deltour L, Hackeng TM, Kiss R, Kloog Y, Poirier F, et al. Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res 2010; 70:6216-24; PMID:20647324; http://dx.doi.org/10.1158/0008-5472.CAN-09-4150
   PubMed Web of Science ®Google Scholar
• Paz A, Haklai R, Elad-Sfadia G, Ballan E, Kloog Y. Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 2001; 20:7486-93; PMID:11709720; http://dx.doi.org/10.1038/sj.onc.1204950
   PubMed Web of Science ®Google Scholar
• van den Brule FA, Waltregny D, Castronovo V. Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients. J Pathol 2001; 193:80-7; PMID:11169519; http://dx.doi.org/10.1002/1096-9896(2000)9999:9999%3c::AID-PATH730%3e3.0.CO;2-2
   PubMed Web of Science ®Google Scholar
• Langbein S, Brade J, Badawi JK, Hatzinger M, Kaltner H, Lensch M, Specht K, André S, Brinck U, Alken P, et al. Gene-expression signature of adhesion/growth-regulatory tissue lectins (galectins) in transitional cell cancer and its prognostic relevance. Histopathology 2007; 51:681-90; PMID:17927590; http://dx.doi.org/10.1111/j.1365-2559.2007.02852.x
   PubMed Web of Science ®Google Scholar
• Chen J, Zhou S-J, Zhang Y, Zhang G-Q, Zha T-Z, Feng Y-Z, Zhang K. Clinicopathological and prognostic significance of galectin-1 and vascular endothelial growth factor expression in gastric cancer. World J Gastroenterol 2013; 19:2073; PMID:23599627; http://dx.doi.org/10.3748/wjg.v19.i13.2073
   PubMed Web of Science ®Google Scholar
• Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Neuzillet C, Albert S, Raymond E, Faivre S. Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev 2014; 40:307-19; PMID:23953240; http://dx.doi.org/10.1016/j.ctrv.2013.07.007
   PubMed Web of Science ®Google Scholar
• Danguy A, Camby I, Kiss R. Galectins and cancer. Biochimica et Biophysica Acta (BBA)-General Subjects 2002; 1572:285-93; http://dx.doi.org/10.1016/S0304-4165(02)00315-X
   PubMed Web of Science ®Google Scholar
• Vespa GN, Lewis LA, Kozak KR, Moran M, Nguyen JT, Baum LG, Miceli MC. Galectin-1 specifically modulates TCR signals to enhance TCR apoptosis but inhibit IL-2 production and proliferation. J Immunol 1999; 162:799-806; PMID:9916701
   PubMedGoogle Scholar
• Blaskó A, Fajka-Boja R, Ion G, Monostori É. How does it act when soluble? Critical evaluation of mechanism of galectin-1 induced T-cell apoptosis. Acta Biologica Hungarica 2011; 62:106-11; http://dx.doi.org/10.1556/ABiol.61.2011.1.11
   PubMed Web of Science ®Google Scholar
• Pang M, He J, Johnson P, Baum LG. CD45-mediated fodrin cleavage during galectin-1 T cell death promotes phagocytic clearance of dying cells. J Immunol 2009; 182:7001-8; PMID:19454697; http://dx.doi.org/10.4049/jimmunol.0804329
   PubMedGoogle Scholar
• Perillo NL, Pace KE, Seilhamer JJ, Baum LG. Apoptosis of T cells mediated by galectin-1. Nature 1995; 378:736-9.
   Google Scholar
• Walzel H, Schulz U, Neels P, Brock J. Galectin-1, a natural ligand for the receptor-type protein tyrosine phosphatase CD45. Immunol Lett 1999; 67:193-202; PMID:10369126; http://dx.doi.org/10.1016/S0165-2478(99)00012-7
   PubMedGoogle Scholar
• Fajka-Boja R, Szemes M, Ion G, Légrádi Á, Caron M, Monostori É. Receptor tyrosine phosphatase, CD45 binds galectin-1 but does not mediate its apoptotic signal in T cell lines. Immunol Lett 2002; 82:149-54; PMID:12008046; http://dx.doi.org/10.1016/S0165-2478(02)00030-5
   PubMedGoogle Scholar
• Nguyen JT, Evans DP, Galvan M, Pace KE, Leitenberg D, Bui TN, Baum LG. CD45 modulates galectin-1-induced T cell death: regulation by expression of core 2 O-glycans. J Immunol 2001; 167:5697-707; PMID:11698442; http://dx.doi.org/10.4049/jimmunol.167.10.5697
   PubMed Web of Science ®Google Scholar
• Pace KE, Hahn HP, Pang M, Nguyen JT, Baum LG. Cutting edge: CD7 delivers a pro-apoptotic signal during galectin-1-induced T cell death. J Immunol 2000; 165:2331-4; PMID:10946254; http://dx.doi.org/10.4049/jimmunol.165.5.2331
   PubMed Web of Science ®Google Scholar
• Le Q-T, Shi G, Cao H, Nelson DW, Wang Y, Chen EY, Zhao S, Kong C, Richardson D, O'Byrne KJ, et al. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 2005; 23:8932-41; PMID:16219933; http://dx.doi.org/10.1200/JCO.2005.02.0206
   PubMed Web of Science ®Google Scholar
• Banh A, Zhang J, Cao H, Bouley DM, Kwok S, Kong C, Giaccia AJ, Koong AC, Le QT. Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res 2011; 71:4423-31; PMID:21546572; http://dx.doi.org/10.1158/0008-5472.CAN-10-4157
   PubMed Web of Science ®Google Scholar
• He J, Baum LG. Presentation of galectin-1 by extracellular matrix triggers T cell death. J Biol Chem 2004; 279:4705-12; PMID:14617626; http://dx.doi.org/10.1074/jbc.M311183200
   PubMed Web of Science ®Google Scholar
• Kovacs-Solyom F, Blasko A, Fajka-Boja R, Katona RL, Vegh L, Novak J, Szebeni GJ, Krenács L, Uher F, Tubak V, et al. Mechanism of tumor cell-induced T-cell apoptosis mediated by galectin-1. Immunol Lett 2010; 127:108-18; PMID:19874850; http://dx.doi.org/10.1016/j.imlet.2009.10.003
   PubMedGoogle Scholar
• Le Mercier M, Mathieu V, Haibe-Kains B, Bontempi G, Mijatovic T, Decaestecker C, Kiss R, Lefranc F. Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses. J Neuropathol Exp Neurol 2008; 67:456-69; PMID:18431251; http://dx.doi.org/10.1097/NEN.0b013e318170f892
   PubMedGoogle Scholar
• Jung T-Y, Jung S, Ryu H-H, Jeong Y-I, Jin Y-H, Jin S-G, Kim IY, Kang SS, Kim HS. Role of galectin-1 in migration and invasion of human glioblastoma multiforme cell lines. J Neurosurg 2008; 109:273-84.
   PubMed Web of Science ®Google Scholar
• Saussez S, Decaestecker C, Lorfevre F, Cucu D-R, Mortuaire G, Chevalier D, Wacreniez A, Kaltner H, André S, Toubeau G, et al. High level of galectin-1 expression is a negative prognostic predictor of recurrence in laryngeal squamous cell carcinomas. Int J Oncol 2007; 30:1109-18; PMID:17390012
   PubMedGoogle Scholar
• Saussez S, Camby I, Toubeau G, Kiss R. Galectins as modulators of tumor progression in head and neck squamous cell carcinomas. Head Neck 2007; 29:874-84; PMID:17315170; http://dx.doi.org/10.1002/hed.20559
   PubMed Web of Science ®Google Scholar
• He J, Baum LG. Endothelial cell expression of galectin-1 induced by prostate cancer cells inhibits T-cell transendothelial migration. Lab Invest 2006; 86:578-90; PMID:16607379
   PubMed Web of Science ®Google Scholar
• Thijssen VL, Hulsmans S, Griffioen AW. The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells. Am J Pathol 2008; 172:545-53; PMID:18202194; http://dx.doi.org/10.2353/ajpath.2008.070938
   PubMed Web of Science ®Google Scholar
• Matarrese P, Tinari A, Mormone E, Bianco GA, Toscano MA, Ascione B, Rabinovich GA, Malorni W. Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding, and fission. J Biol Chem 2005; 280:6969-85; PMID:15556941; http://dx.doi.org/10.1074/jbc.M409752200
   PubMed Web of Science ®Google Scholar
• Cedeno-Laurent F, Opperman M, Barthel SR, Kuchroo VK, Dimitroff CJ. Galectin-1 triggers an immunoregulatory signature in Th cells functionally defined by IL-10 expression. J Immunol 2012; 188:3127-37; PMID:22345665; http://dx.doi.org/10.4049/jimmunol.1103433
   PubMed Web of Science ®Google Scholar
• Croci DO, Salatino M, Rubinstein N, Cerliani JP, Cavallin LE, Leung HJ, Ouyang J, Ilarregui JM, Toscano MA, Domaica CI, et al. Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma. J Exp Med 2012; 209:1985-2000; PMID:23027923; http://dx.doi.org/10.1084/jem.20111665
   PubMed Web of Science ®Google Scholar
• Heslop HE. A less sour sweet; blocking galectin. Blood 2011; 117:4165-6; PMID:21511962; http://dx.doi.org/10.1182/blood-2011-03-337683
   PubMedGoogle Scholar
• Ito K, Scott SA, Cutler S, Dong L-F, Neuzil J, Blanchard H, Ralph SJ. Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress. Angiogenesis 2011; 14:293-307; PMID:21523436; http://dx.doi.org/10.1007/s10456-011-9213-5
   PubMed Web of Science ®Google Scholar
• Delaine T, Cumpstey I, Ingrassia L, Mercier ML, Okechukwu P, Leffler H, Kiss R, Nilsson UJ. Galectin-inhibitory thiodigalactoside ester derivatives have antimigratory effects in cultured lung and prostate cancer cells. J Med Chem 2008; 51:8109-14; PMID:19053747; http://dx.doi.org/10.1021/jm801077j
   PubMed Web of Science ®Google Scholar
• Iurisci I, Cumashi A, Sherman AA, Tsvetkov YE, Tinari N, Piccolo E, D'Egidio M, Adamo V, Natoli C, Rabinovich GA, et al. Synthetic inhibitors of galectin-1 and-3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. Anticancer Res 2009; 29:403-10; PMID:19331179
   PubMed Web of Science ®Google Scholar
• Rabinovich GA, Cumashi A, Bianco GA, Ciavardelli D, Iurisci I, D'Egidio M, Piccolo E, Tinari N, Nifantiev N, Iacobelli S. Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology 2006; 16:210-20; PMID:16282605; http://dx.doi.org/10.1093/glycob/cwj056
   PubMed Web of Science ®Google Scholar
• Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91:479-89; PMID:9390557; http://dx.doi.org/10.1016/S0092-8674(00)80434-1
   PubMed Web of Science ®Google Scholar
• Mellado M, de Ana AMn, Moreno MC, Martínez-A C, Rodríguez-Frade JM. A potential immune escape mechanism by melanoma cells through the activation of chemokine-induced T cell death. Curr Biol 2001; 11:691-6; PMID:11369232; http://dx.doi.org/10.1016/S0960-9822(01)00199-3
   PubMedGoogle Scholar
• Lin S, Wan S, Sun L, Hu J, Fang D, Zhao R, Yuan S, Zhang L. Chemokine C‐C motif receptor 5 and C‐C motif ligand 5 promote cancer cell migration under hypoxia. Cancer Sci 2012; 103:904-12; PMID:22380870; http://dx.doi.org/10.1111/j.1349-7006.2012.02259.x
   PubMedGoogle Scholar
• Mrowietz U, Schwenk U, Maune S, Bartels J, Küpper M, Fichtner I, Schröder JM, Schadendorf D. The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. British J Cancer 1999; 79:1025; PMID:10098731; http://dx.doi.org/10.1038/sj.bjc.6690164
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Colombatti A. The inflammatory chemokine CCL5 and cancer progression. Mediators Inflamm 2014; 2014; PMID:24523569; http://dx.doi.org/10.1155/2014/292376
   PubMedGoogle Scholar
• Kato T, Fujita Y, Nakane K, Mizutani K, Terazawa R, Ehara H, Kanimoto Y, Kojima T, Nozawa Y, Deguchi T, et al. CCR1/CCL5 interaction promotes invasion of taxane-resistant PC3 prostate cancer cells by increasing secretion of MMPs 2/9 and by activating ERK and Rac signaling. Cytokine 2013; 64:251-7; PMID:23876400; http://dx.doi.org/10.1016/j.cyto.2013.06.313
   PubMed Web of Science ®Google Scholar
• Yaal-Hahoshen N, Shina S, Leider-Trejo L, Barnea I, Shabtai EL, Azenshtein E, Greenberg I, Keydar I, Ben-Baruch A. The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin Cancer Res 2006; 12:4474-80; PMID:16899591; http://dx.doi.org/10.1158/1078-0432.CCR-06-0074
   PubMed Web of Science ®Google Scholar
• Lv D, Zhang Y, Kim H-J, Zhang L, Ma X. CCL5 as a potential immunotherapeutic target in triple-negative breast cancer. Cell Mol Immunol 2013; 10:303-10; PMID:23376885; http://dx.doi.org/10.1038/cmi.2012.69
   PubMed Web of Science ®Google Scholar
• Sugasawa H, Ichikura T, Kinoshita M, Ono S, Majima T, Tsujimoto H, Chochi K, Hiroi S, Takayama E, Saitoh D, et al. Gastric cancer cells exploit CD4+ cell‐derived CCL5 for their growth and prevention of CD8+ cell‐involved tumor elimination. Int J Cancer 2008; 122:2535-41; http://dx.doi.org/10.1002/ijc.23401
   PubMed Web of Science ®Google Scholar
• Chang L-Y, Lin Y-C, Mahalingam J, Huang C-T, Chen T-W, Kang C-W, Peng HM, Chu YY, Chiang JM, Dutta A, et al. Tumor-Derived Chemokine CCL5 Enhances TGF-β-Mediated Killing of CD8+ T Cells in Colon Cancer by T-Regulatory Cells. Cancer Res 2012; 72:1092-102; PMID:22282655; http://dx.doi.org/10.1158/0008-5472.CAN-11-2493
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhu J, Hong X, Zhou Y, Ren K, Shu X, Wang Q. The membrane molecule RCAS1 induces immune cell apoptosis via the RCAS1-RCAS1R pathway. Int J Mol Med 2013; 31:1319-26; PMID:23563217
   PubMedGoogle Scholar
• Matsushima T, Nakashima M, Oshima K, Abe Y, Nishimura J, Nawata H, Watanabe T, Muta K. Receptor binding cancer antigen expressed on SiSo cells, a novel regulator of apoptosis of erythroid progenitor cells. Blood 2001; 98:313-21; PMID:11435298; http://dx.doi.org/10.1182/blood.V98.2.313
   PubMedGoogle Scholar
• Okada K, Nakashima M, Komuta K, Hashimoto S, Okudaira S, Baba N, Hishikawa Y, Koji T, Kanematsu T, Watanabe T. Expression of tumor-associated membrane antigen, RCAS1, in human colorectal carcinomas and possible role in apoptosis of tumor-infiltrating lymphocytes. Modern Pathol 2003; 16:679-85; PMID:12861064; http://dx.doi.org/10.1097/01.MP.0000074732.17945.6C
   PubMedGoogle Scholar
• Han Y, Qin W, Huang G. Knockdown of RCAS1 expression by RNA interference recovers T cell growth and proliferation. Cancer Lett 2007; 257:182-90; PMID:17825484; http://dx.doi.org/10.1016/j.canlet.2007.07.016
   PubMedGoogle Scholar